UPDATED – 2022 Safety Protocols

CHI has instituted mandatory health and safety protocols for all in-person participants. We are excited to bring our community back together in 2022, with trust and safety as our top priorities. All in-person participants are required to:

  • Provide proof of full vaccination against COVID-19. You will be asked to present your vaccination card (or a photo of it) at registration.
  • Have a negative COVID-19 test result from an FDA-authorized over-the-counter antigen test within 24 hours prior to arriving at the event. You will be asked your results at registration.
Final Agenda Available

Conference Programs

Viral Vector Characterization - April 11
Vector Engineering & Design - April 12
Advancing Gene Therapy to the Clinic - April 13

Bringing Together Vector Engineers and Scientists to Accelerate Gene Therapy Development

The past five years have been a critical turning point for gene therapy. From the first approved oligonucleotide-based therapy to the success of CAR-T cell therapies, followed by the recent in-vivo gene therapies and the emerging gene editing strategies, these gene therapeutics are not only life-changing for patients with rare diseases, but are also laying the foundation for potential treatments of other unmet medical needs.

Given the highly dynamic and competitive nature of the gene therapy industry, scientists are facing a multitude of challenges as they move from bench to clinic. This event thus hopes to gather the knowledge and expertise of scientists in vector engineering, analytics, immunogenicity assessments, preclinical development and clinical translation, to help accelerate next generation gene therapy development.



Potency Assay Development and Validation for Gene Therapy Products

Lyndi Rice, PhD

Lyndi Rice, PhD
Head, QC Viral Vectors, Biomarin

AAV Capsid Engineering to Increase Human Tissue Tropism and Transduction

Matthias Hebben, PhD

Matthias Hebben, PhD
Global Vice President, Technology Development, LogicBio Therapeutics Inc.

Gene Therapy for Young Onset PD: Focus on the Small to Go Big

Jennifer Johnston, PhD

Jennifer Johnston, PhD
Co-Founder & CEO, NysnoBio

Join Our Growing Community of Scientists & Engineers


Mimi Langley
Senior Conference Director
T: 781.972.5439


Companies A-K
Ashley Parsons

Manager, Business Development

Companies L-Z
Jason Gerardi

Sr. Manager, Business Development


Bethany Gray
Director of Product Marketing
T: 781.972.5494